Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Jan 8

PMID 39766127

Authors

Patrick Mun Yew Chan

Kay Hsiang Ong

Sherwin Kuah

E Jan Sim

Juliana Chen

Mui Heng Goh

Wei-Wen Ang

Ern Yu Tan

Affiliations

Soon will be listed here.

Abstract

Background: With greater awareness and increased screening, cancers are increasingly being diagnosed at stage I. Women with these small node-negative tumours have excellent survival prospects after surgery, but many women, especially those with triple-negative and human epidermal growth factor receptor (HER)-2-positive tumours, still receive adjuvant systemic treatments to reduce the recurrence risk.

Aims: We review the outcomes of women diagnosed with stage I (T1N0M0) tumours in our unit and examine the effect of systemic chemotherapy with/without targeted therapy on recurrence patterns and survival outcomes.

Results: We reviewed 643 women diagnosed with T1N0M0 disease over a 10-year period. Five-year recurrence-free survival (RFS) was 96.6% and the 10-year RFS was 95.5%. Recurrence occurred in 4.7% of the women and was limited to locoregional sites in two-thirds of the instances. Systemic recurrences developed in 12 women, all of whom had ER-positive/HER2-negative disease. The mode of surgery emerged as the only independent predictor of recurrence. Recurrence was highest in women treated with wide local excision (WLE) alone ( < 0.05), but not in those who had received breast radiation after WLE ( = 0.112). Systemic chemotherapy, with or without anti-HER2 therapy, was discussed with 334 women, of whom 50.6% received the treatment; these women were more often younger and had triple-negative or HER2-positive tumours ( < 0.001). Women who received chemotherapy showed a non-significant tendency to develop locoregional recurrence ( = 0.104), but the number of systemic recurrences were similar to those documented in women who had not received chemotherapy. Chemotherapy and/or targeted treatment was not observed to have a significant effect on 5-year recurrence-free survival ( = 0.444).

Conclusions: Stage I cancers have excellent survival outcomes. An optimal local surgical treatment is important and we did not find chemotherapy and/or targeted therapy to produce any significant differences in survival.

References

Jones S, Collea R, Paul D, Sedlacek S, Favret A, Gore Jr I . Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013; 14(11):1121-1128. DOI: 10.1016/S1470-2045(13)70384-X. View

Ring A, Harder H, Langridge C, Ballinger R, Fallowfield L . Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making. Ann Oncol. 2013; 24(5):1211-9. DOI: 10.1093/annonc/mds642. View

Metzger-Filho O, Sun Z, Viale G, Price K, Crivellari D, Snyder R . Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013; 31(25):3083-90. PMC: 3753700. DOI: 10.1200/JCO.2012.46.1574. View

Hassing C, Mejdahl M, Laenkholm A, Kroman N, Knoop A, Tvedskov T . Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study. Breast Cancer Res Treat. 2022; 196(1):197-206. DOI: 10.1007/s10549-022-06724-y. View

Taylor C, McGale P, Probert J, Broggio J, Charman J, Darby S . Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ. 2023; 381:e074684. PMC: 10261971. DOI: 10.1136/bmj-2022-074684. View

Voduc K, Cheang M, Tyldesley S, Gelmon K, Nielsen T, Kennecke H . Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28(10):1684-91. DOI: 10.1200/JCO.2009.24.9284. View

Tabar L, Fagerberg G, Day N, Duffy S, Kitchin R . Breast cancer treatment and natural history: new insights from results of screening. Lancet. 1992; 339(8790):412-4. DOI: 10.1016/0140-6736(92)90090-p. View

Sharma P . Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol. 2018; 19(5):22. DOI: 10.1007/s11864-018-0539-8. View

Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M . Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353(17):1784-92. DOI: 10.1056/NEJMoa050518. View

10.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A . Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002; 347(16):1227-32. DOI: 10.1056/NEJMoa020989. View

11.

Stravodimou A, Voutsadakis I . Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond. Expert Rev Anticancer Ther. 2024; 24(3-4):117-135. DOI: 10.1080/14737140.2024.2330601. View

12.

Bland K, Menck H, Morrow M, Winchester D, WINCHESTER D . The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998; 83(6):1262-73. DOI: 10.1002/(sici)1097-0142(19980915)83:6<1262::aid-cncr28>3.0.co;2-2. View

13.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

14.

Vaz-Luis I, Ottesen R, Hughes M, Mamet R, Burstein H, Edge S . Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014; 32(20):2142-50. PMC: 4076026. DOI: 10.1200/JCO.2013.53.1608. View

15.

Tolaney S, Barry W, Dang C, Yardley D, Moy B, Marcom P . Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015; 372(2):134-41. PMC: 4313867. DOI: 10.1056/NEJMoa1406281. View

16.

Cognetti F, Biganzoli L, De Placido S, Del Mastro L, Masetti R, Naso G . Multigene tests for breast cancer: the physician's perspective. Oncotarget. 2021; 12(9):936-947. PMC: 8092339. DOI: 10.18632/oncotarget.27948. View

17.

Wu C, Huang O, Wu J, Shen K, Chen X, Zhu S . Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis. Gland Surg. 2023; 12(10):1375-1386. PMC: 10660177. DOI: 10.21037/gs-23-189. View

18.

Yang Z, Chen Y, Liu X, Cui J, Hu Y, Wei W . Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis. Cancer Treat Res Commun. 2020; 25:100211. DOI: 10.1016/j.ctarc.2020.100211. View

19.

van Maaren M, de Munck L, Strobbe L, Sonke G, Westenend P, Smidt M . Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2018; 144(2):263-272. DOI: 10.1002/ijc.31914. View

20.

Shen K, Yao L, Zhu J, Gu X, Wang J, Qian W . Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort. BMC Cancer. 2022; 22(1):863. PMC: 9358893. DOI: 10.1186/s12885-022-09952-z. View